Ticker: CVKD

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) - Quick internal read Management is advancing tecarfarin into late-stage clinical activity (announced trial plans for ESKD patients on August 5, 2025) while burning cash to support operations and public-company overhead. The company used its ATM program ...

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) - Q1 2025 Financial Summary Cadrenal Therapeutics reported its quarterly financial results for the period ending March 31, 2025, revealing significant developments in its ongoing operations and financial performance. Positive Aspects: Total Revenue: Rev...